KODIAK SCIENCES INC. Operating Income
KODIAK SCIENCES INC. (KOD) reported Operating Income of -$66.84 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-13
- KODIAK SCIENCES INC. operating income (loss) for the quarter ending 2026-06-30 was -$66.84M.
- KODIAK SCIENCES INC. operating income (loss) for the quarter ending 2026-03-31 was -$59.78M.
- KODIAK SCIENCES INC. operating income (loss) for the quarter ending 2025-12-31 was -$57.45M.
- KODIAK SCIENCES INC. operating income (loss) for the quarter ending 2025-09-30 was -$62.35M.
- KODIAK SCIENCES INC. operating income (loss) for fiscal 2025 was -$234.39M.
- KODIAK SCIENCES INC. operating income (loss) for fiscal 2024 was -$186.85M.
- KODIAK SCIENCES INC. operating income (loss) for fiscal 2023 was -$277.32M.
- KODIAK SCIENCES INC. operating income (loss) for fiscal 2022 was -$341.38M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 3 month as first filed | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 9 month as first filed | Operating Income (Loss) 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$66.84M 10-Q · filed 2026-08-13 | -$126.61M 10-Q · filed 2026-08-13 | -$184.07M derived: sum of 3 quarters · filed 2026-08-13 | -$246.42M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2026-03-31 | -$59.78M 10-Q · filed 2026-05-07 | -$117.23M derived: sum of 2 quarters · filed 2026-05-07 | -$179.58M derived: sum of 3 quarters · filed 2026-05-07 | -$235.09M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-12-31 | -$57.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$119.81M derived: sum of 2 quarters · filed 2026-03-31 | -$175.31M derived: sum of 3 quarters · filed 2026-08-13 | -$234.39M 10-K · filed 2026-03-31 | ||
| 2025-09-30 | -$62.35M 10-Q · filed 2025-11-13 | -$117.86M derived: sum of 2 quarters · filed 2026-08-13 | -$176.94M 10-Q · filed 2025-11-13 | -$223.11M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-06-30 | -$55.51M 10-Q · filed 2026-08-13 | -$114.58M 10-Q · filed 2026-08-13 | -$160.76M derived: sum of 3 quarters · filed 2026-08-13 | -$207.39M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-03-31 | -$59.07M 10-Q · filed 2026-05-07 | -$105.25M derived: sum of 2 quarters · filed 2026-05-07 | -$151.88M derived: sum of 3 quarters · filed 2026-05-07 | -$199.87M derived: sum of 4 quarters · filed 2026-05-07 | ||
| 2024-12-31 | -$46.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$92.81M derived: sum of 2 quarters · filed 2026-03-31 | -$140.79M derived: sum of 3 quarters · filed 2026-03-31 | -$186.85M 10-K · filed 2026-03-31 | ||
| 2024-09-30 | -$46.63M 10-Q · filed 2025-11-13 | -$94.61M derived: sum of 2 quarters · filed 2025-11-13 | -$140.67M 10-Q · filed 2025-11-13 | -$204.04M derived: sum of 4 quarters · filed 2026-03-31 | ||
| 2024-06-30 | -$47.98M 10-Q · filed 2025-08-13 | -$94.04M 10-Q · filed 2025-08-13 | -$157.41M derived: sum of 3 quarters · filed 2026-03-31 | -$211.91M derived: sum of 4 quarters · filed 2026-03-31 | ||
| 2024-03-31 | -$46.05M 10-Q · filed 2025-05-14 | -$109.43M derived: sum of 2 quarters · filed 2026-03-31 | -$163.93M derived: sum of 3 quarters · filed 2026-03-31 | -$248.76M derived: sum of 4 quarters · filed 2026-03-31 | ||
| 2023-12-31 | -$63.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$117.87M derived: sum of 2 quarters · filed 2026-03-31 | -$202.71M derived: sum of 3 quarters · filed 2026-03-31 | -$277.32M 10-K · filed 2026-03-31 | ||
| 2023-09-30 | -$54.50M 10-Q · filed 2024-11-14 | -$139.33M derived: sum of 2 quarters · filed 2024-11-14 | -$213.95M 10-Q · filed 2024-11-14 | -$288.01M derived: sum of 4 quarters · filed 2025-03-27 | ||
| 2023-06-30 | -$84.83M 10-Q · filed 2024-08-14 | -$159.45M 10-Q · filed 2024-08-14 | -$233.51M derived: sum of 3 quarters · filed 2025-03-27 | -$312.99M derived: sum of 4 quarters · filed 2025-03-27 | ||
| 2023-03-31 | -$74.61M 10-Q · filed 2024-05-15 | -$148.68M derived: sum of 2 quarters · filed 2025-03-27 | -$228.16M derived: sum of 3 quarters · filed 2025-03-27 | -$320.23M derived: sum of 4 quarters · filed 2025-03-27 | ||
| 2022-12-31 | -$74.07M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$153.54M derived: sum of 2 quarters · filed 2025-03-27 | -$245.61M derived: sum of 3 quarters · filed 2025-03-27 | -$341.38M 10-K · filed 2025-03-27 | ||
| 2022-09-30 | -$79.48M 10-Q · filed 2023-11-14 | -$171.55M derived: sum of 2 quarters · filed 2023-11-14 | -$267.31M 10-Q · filed 2023-11-14 | -$360.36M derived: sum of 4 quarters · filed 2023-11-14 | ||
| 2022-06-30 | -$92.07M 10-Q · filed 2023-08-14 | -$187.84M 10-Q · filed 2023-08-14 | -$280.88M derived: sum of 3 quarters · filed 2023-08-14 | -$348.42M derived: sum of 4 quarters · filed 2023-08-14 | ||
| 2022-03-31 | -$95.77M 10-Q · filed 2023-05-15 | -$188.82M derived: sum of 2 quarters · filed 2023-05-15 | -$256.35M derived: sum of 3 quarters · filed 2023-05-15 | -$312.26M derived: sum of 4 quarters · filed 2023-05-15 | ||
| 2021-12-31 | -$93.05M 10-K · filed 2022-03-01 | -$160.58M derived: sum of 2 quarters · filed 2022-11-09 | -$216.49M derived: sum of 3 quarters · filed 2022-11-09 | -$267.05M 10-K · filed 2024-03-28 | ||
| 2021-09-30 | -$67.53M 10-Q · filed 2022-11-09 | -$123.44M derived: sum of 2 quarters · filed 2022-11-09 | -$174.00M 10-Q · filed 2022-11-09 | -$220.84M derived: sum of 4 quarters · filed 2022-11-09 | ||
| 2021-06-30 | -$55.91M 10-Q · filed 2022-08-09 | -$106.47M 10-Q · filed 2022-08-09 | -$153.31M derived: sum of 3 quarters · filed 2022-08-09 | -$189.97M derived: sum of 4 quarters · filed 2022-08-09 | ||
| 2021-03-31 | -$50.56M 10-Q · filed 2022-05-10 | -$97.40M derived: sum of 2 quarters · filed 2022-05-10 | -$134.06M derived: sum of 3 quarters · filed 2022-05-10 | -$160.84M derived: sum of 4 quarters · filed 2022-05-10 | ||
| 2020-12-31 | -$46.84M 10-K · filed 2022-03-01 | -$83.50M derived: sum of 2 quarters · filed 2022-03-01 | -$110.28M derived: sum of 3 quarters · filed 2022-03-01 | -$136.01M 10-K · filed 2023-03-28 | ||
| 2020-09-30 | -$36.66M 10-K · filed 2022-03-01 | -$63.44M derived: sum of 2 quarters · filed 2022-03-01 | -$89.17M 10-Q · filed 2021-11-09 | -$105.35M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2020-06-30 | -$26.78M 10-K · filed 2022-03-01 | -$52.50M 10-Q · filed 2021-08-09 | -$68.69M derived: sum of 3 quarters · filed 2022-03-01 | -$81.42M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2020-03-31 | -$25.72M 10-K · filed 2022-03-01 | -$41.91M derived: sum of 2 quarters · filed 2022-03-01 | -$54.64M derived: sum of 3 quarters · filed 2022-03-01 | -$66.45M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2019-12-31 | -$16.18M 10-K · filed 2021-03-01 | -$28.92M derived: sum of 2 quarters · filed 2021-03-01 | -$40.73M derived: sum of 3 quarters · filed 2021-03-01 | -$49.19M 10-K · filed 2022-03-01 | ||
| 2019-09-30 | -$12.73M 10-K · filed 2021-03-01 | -$24.55M derived: sum of 2 quarters · filed 2021-03-01 | -$33.01M 10-Q · filed 2020-11-09 | -$42.36M derived: sum of 4 quarters · filed 2021-03-01 | ||
| 2019-06-30 | -$11.81M 10-K · filed 2021-03-01 | -$20.27M 10-Q · filed 2020-08-10 | -$29.63M derived: sum of 3 quarters · filed 2021-03-01 | -$36.01M derived: sum of 4 quarters · filed 2021-03-01 | ||
| 2019-03-31 | -$8.46M 10-K · filed 2021-03-01 | -$17.82M derived: sum of 2 quarters · filed 2021-03-01 | -$24.20M derived: sum of 3 quarters · filed 2021-03-01 | -$29.29M derived: sum of 4 quarters · filed 2021-03-01 | ||
| 2018-12-31 | -$9.36M 10-K · filed 2020-03-16 | -$15.74M derived: sum of 2 quarters · filed 2020-03-16 | -$20.83M derived: sum of 3 quarters · filed 2020-03-16 | -$26.37M 10-K · filed 2021-03-01 | ||
| 2018-09-30 | -$6.38M 10-K · filed 2020-03-16 | -$6.38K 10-Q · filed 2018-11-16 | -$11.47M derived: sum of 2 quarters · filed 2020-03-16 | -$17.02M 10-Q · filed 2019-11-12 | -$17.02K 10-Q · filed 2018-11-16 | -$26.77M derived: sum of 4 quarters · filed 2020-03-16 |
| 2018-06-30 | -$5.09M 10-K · filed 2020-03-16 | -$10.64M 10-Q · filed 2019-08-14 | -$20.39M derived: sum of 3 quarters · filed 2020-03-16 | -$24.37M derived: sum of 4 quarters · filed 2020-03-16 | ||
| 2018-03-31 | -$5.55M 10-K · filed 2020-03-16 | -$15.30M derived: sum of 2 quarters · filed 2020-03-16 | -$19.28M derived: sum of 3 quarters · filed 2020-03-16 | -$26.02M derived: sum of 4 quarters · filed 2020-03-16 | ||
| 2017-12-31 | -$9.76M 10-K · filed 2019-03-27 | -$13.74M derived: sum of 2 quarters · filed 2019-03-27 | -$20.48M derived: sum of 3 quarters · filed 2019-03-27 | -$25.52M 10-K · filed 2020-03-16 | ||
| 2017-09-30 | -$3.98M 10-K · filed 2019-03-27 | -$3.98K 10-Q · filed 2018-11-16 | -$10.72M derived: sum of 2 quarters · filed 2019-03-27 | -$15.76K 10-Q · filed 2018-11-16 | ||
| 2017-06-30 | -$6.74M 10-K · filed 2019-03-27 | -$11.79M derived: sum of 2 quarters · filed 2019-03-27 | ||||
| 2017-03-31 | -$5.04M 10-K · filed 2019-03-27 | |||||
| 2016-12-31 | -$17.15M 10-K · filed 2019-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |